Nuvation Bio, Inc. (NUVB)
NYSEHealth CareBiotechnologySnapshot 2026-09-04
$6.81+0.59%
Close 2026-09-04 · 1-day change
NYSEHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · NUVB
How strong the business is — where it ranks within its sector on capital efficiency and cash generation, and how well management has been executing.
How this business ranks within health care on a research-validated quality screen. As of 2026-09-04.
The screen ranks NUVB against its sector on four durable signals: share dilution, return on capital, free-cash-flow yield, and FCF margin. Historically the highest-quality names tended toward better typical outcomes and fewer bad years over multi-year holds (strongest at three years, modest at one), and that pattern showed up even before the price moved. It characterizes business quality, not price direction.
Each leg is a sector-relative percentile (higher is better); 4 of 4 legs were available for this name. The composite is built from these four; the raw value follows each percentile for context.
A forward quality tilt, not a price prediction, and context for your own research rather than a recommendation. Not investment advice.
How management runs the business: capital, margins, balance sheet, and how reliably they guide and deliver.
Each factor is a parallel diagnostic with a clear read of what it shows and how names like it have historically fared. Never aggregated into a single score.
Operating income rose in 2 of the last 3 quarter-over-quarter moves. Historically, Health Care names rated neutral grew net income 51% of the time over the next year (vs 41% for the rest of the cohort, n=13363).
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
A guidance track record builds as the company issues and delivers on guidance.
Priorities management has stated in recent disclosures, with status and evidence drawn from earnings calls, filings, and press releases.
Continue to grow net product revenue and patient starts for IBTROZI, focusing on TKI-naïve patients and expanding market share in advanced ROS1-positive NSCLC.
Stated as a priority in 2 of last 2 quarters. Net product revenue from IBTROZI increased from $18.5 million in 2026-Q1 to $23.2 million in 2026-Q2. Management emphasized ~85% of new patients were TKI-naïve with ~30% quarter-over-quarter growth in this segment, indicating delivering growth and adoption.
“IBTROZI is now the most prescribed ROS1 TKI in 2026, ~85% new patients TKI-naïve, 30% QoQ growth”
“Majority of ~200 patients started on IBTROZI in Q1 2026 were TKI-naïve, highlighting continued momentum”
Expand clinical development and global rights for safusidenib to address IDH1-mutant glioma, including new Phase 3 and Phase 2 studies.
Stated as a priority in 2 of last 2 quarters. Management acquired Japan rights to safusidenib and initiated new pivotal Phase 3 and Phase 2 studies in IDH1-mutant glioma. While no direct financial metrics are reported, the expanded clinical program and global rights acquisition indicate active advancement consistent with stated goals.
“Announced significant expansion of safusidenib clinical program with new Phase 3 and Phase 2 studies”
Continue exploration of preclinical candidates for the novel drug-drug conjugate platform with updates expected by year-end 2026.
Stated as a priority in 2 of last 2 quarters. Management reiterated ongoing exploration of preclinical candidates for the DDC platform with planned updates by year-end 2026. No financial or clinical milestones reported yet, indicating recurring focus with limited substantive delivery so far.
“Continue to explore new preclinical candidates for DDC platform, updates expected by year-end 2026”
Strengthen financial position through convertible notes offerings and manage cash to support ongoing operations and investments.
Stated as a priority in 2 of last 2 quarters. Cash, cash equivalents, and marketable securities increased from $533.7 million in 2026-Q1 to $661.0 million in 2026-Q2. Management completed a $287.5 million convertible senior notes offering including Greenshoe exercise, enhancing capital flexibility. The trajectory shows delivering on financial strength and capital management.
Focus on improving operating income and net income through revenue growth and expense management.
Stated as a priority in 2 of last 2 quarters. Net income was positive $5.4 million in 2026-Q1 but declined to a net loss of $62.8 million in 2026-Q2. Despite revenue growth, profitability deteriorated in Q2, indicating limited progress on sustained positive net income.
“Net loss of $62.8 million reported for Q2 2026”
Over the trailing year it converted 0.89x of net income into operating cash flow.
Most sensitive to the broad stock market.
Not enough signal to read sensitivity to the US dollar, long-term interest rates, real (inflation-adjusted) rates, Fed net liquidity (low R² over the window).
10 material management or governance events in the past 24 months, led by M&A activity. Historically, Health Care names rated neutral grew net income 53% of the time over the next year (vs 49% for the rest of the cohort, n=5275).
Not investment advice. As of 2026-09-04.
“Acquired Japan rights to safusidenib, enabling global development and commercialization”
“Well on track to provide updates on DDC platform later this year”
“Completed convertible notes offering with net proceeds of approx. $279.1 million”
“Strong balance sheet with cash, cash equivalents, and marketable securities of $533.7 million”
“Net income of $5.4 million reported for Q1 2026”